A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

Inclusion Criteria: * Subject participated in study C87085 \[NCT00552058\] in which the subject completed the study at Week 6 * Subject is capable of providing informed consent, which must be obtained prior to any study related procedures * Have a chest X-ray taken at Visit 1 that is read by a qualified radiologist or pulmonary physician, with no evidence of current active Tuberculosis (TB) or old inactive TB * Subject has taken a TB survey and is committed to comply with TB prophylaxis if applicable Exclusion Criteria: * Subject is experiencing an ongoing serious adverse event assessed as being related to study medication or is experiencing a serious adverse event that is still not assessable * Subject has an intercurrent illness that requires termination of treatment, such as a serious infection (e.g. TB, pneumonia, sepsis, pyelonephritis, fistula abscess) * Subject is non-compliant with TB prophylactic treatment (if applicable) * Subject has had a chest X-ray at Visit 1 that shows an abnormality suggestive of a malignancy or active infection, including TB * Female who is pregnant or breast feeding * Female of child bearing age or post puberty males not practicing effective birth control * Subject is expecting to receive any live virus or bacterial vaccination within 3 months of first Study Medication administration, during the trial or 3 months after last dose of study drug